Werewolf Therapeutics Earnings Call Transcripts
Fiscal Year 2025
-
The platform leverages native cytokines and advanced masking to enable safe, targeted immunotherapy, with WTX-124 showing strong safety and efficacy in multiple tumor types. Key milestones ahead include FDA meetings, new data releases, and pipeline expansion.
-
The session highlighted progress on conditionally activated biologics, with WTX-124 showing promising safety and efficacy in multiple cancer types and a pivotal year ahead for regulatory discussions. Updates on the T-cell engager platform and WTX-330 are expected later this year.
-
The company highlighted progress on its PREDATOR platform, with WTX-124 showing promising monotherapy and combination activity in multiple cancers and plans for FDA engagement this year. Pipeline advances include IL-12 and IL-10 programs, with strong cash reserves supporting operations into late 2026.
-
The conference highlighted progress on two clinical-stage INDUKINE programs, WTX-124 and WTX-330, both showing promising safety and efficacy in difficult-to-treat cancers. Expansion trials are ongoing, with key data readouts and regulatory milestones expected in late 2024 and 2025.
-
The discussion highlighted advances in conditional cytokine therapies, with WTX-124 showing promising durable responses in difficult-to-treat cancers and ongoing expansion in key indications. Strategic focus includes leveraging INDUKINE technology for next-gen biologics and optimizing IL-12 dosing.
Fiscal Year 2024
-
INDUKINE prodrugs show promising efficacy and safety in post-checkpoint cancer settings, with WTX-124 and WTX-330 advancing through clinical trials. Durable responses and manageable toxicity support expansion, with key monotherapy data expected in 2025.
-
WTX-124 demonstrated favorable safety and promising efficacy in heavily pretreated patients, with durable responses and strong biomarker activation at higher doses. Expansion arms are enrolling at 18mg, and combination data show early activity, supporting further development in multiple tumor types.